Ivonib/Ivitinib dosage form, capsule or tablet

Ivosidenib, trade nameTibsovo, is an anti-cancer drug used to treat acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several cancers. Ivonib is an isocitrate dehydrogenase-1 inhibitor that reduces the abnormal production of the tumor metabolite 2-hydroxyglutarate (2-HG), which leads to the differentiation of malignant cells.

Avosidenib is mainly available in the form of tablets, not capsules. As an oral targeted drug targeting IDH1 gene mutations, this drug is available in many countries and regions and has received widespread attention for its unique efficacy. The usual specification of ivonib tablets is 250 mg per tablet, which allows patients to adjust and control the dosage according to medical advice. In practical applications, doctors will determine the number of tablets the patient needs to take daily based on the patient's specific conditions, such as weight, severity of the condition, and whether there are other complications.

Avosidenib, as an oral targeted inhibitor of the IDH1 enzyme, is mainly used to treat acute myeloid leukemia (AML) patients with IDH1 mutations, including adult patients with relapsed or refractory AML, as well as newly diagnosed AML patients who are older or cannot use intensive induction chemotherapy due to comorbidities. In addition, ivosidenib is also approved for the treatment of adult patients with previously treated locally advanced or metastatic cholangiocarcinoma carrying IDH1 mutations, although this indication has not yet been approved in the Chinese market.

When taking ivonib, patients need to follow the doctor's instructions, take the medicine on time and in the right amount, and pay close attention to possible side effects and adverse reactions. At the same time, patients also need to regularly monitor hematological parameters and liver function to ensure the safety and effectiveness of the drug.